Page last updated: 2024-08-23

etoposide and ganglioside, gd2

etoposide has been researched along with ganglioside, gd2 in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (50.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hovi, L; Saarinen, UM; Sariola, H	1
Bonilla, MA; Canete, A; Cheung, IY; Cheung, NK; Heller, G; Kushner, B; Larson, SM; Yeh, SJ	1
Cheung, NK; Kramer, K; Kushner, BH; LaQuaglia, MP; Modak, S; Yataghene, K	1
Bean, AJ; Brown, BS; Celia, C; Mobli, K; Patanam, T; Tasciotti, E; Zage, PE	1

Trials

1 trial(s) available for etoposide and ganglioside, gd2

Article	Year
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Dec-15, Volume: 22, Issue:24 Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gangliosides; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infant; Male; Neuroblastoma; Risk Factors; Treatment Outcome; Vincristine	2004

Article

Year

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Dec-15, Volume: 22, Issue:24

Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gangliosides; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infant; Male; Neuroblastoma; Risk Factors; Treatment Outcome; Vincristine

2004

Other Studies

3 other study(ies) available for etoposide and ganglioside, gd2

Article	Year
Recurrent disseminated retinoblastoma treated by high-dose chemotherapy, total body irradiation, and autologous bone marrow rescue. The American journal of pediatric hematology/oncology, 1991,Fall, Volume: 13, Issue:3 Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Bone Neoplasms; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Eye Enucleation; Eye Neoplasms; Female; Gangliosides; Humans; Mandibular Neoplasms; Methotrexate; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Remission Induction; Retinoblastoma; Transplantation, Autologous; Vincristine; Whole-Body Irradiation	1991
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer research, 1994, Apr-15, Volume: 54, Issue:8 Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Enzyme-Linked Immunosorbent Assay; Etoposide; Gangliosides; Humans; Melphalan; Mice; Neoplasm Staging; Neuroblastoma; Prognosis; Radiotherapy Dosage; Survival Analysis; Survival Rate; Thiotepa	1994
Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer biology & therapy, 2014, Volume: 15, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Proliferation; Clathrin; Endocytosis; Etoposide; Gangliosides; Humans; Immunoglobulin G; Liposomes; Neoplasms; Topoisomerase Inhibitors; Tumor Cells, Cultured	2014